AVTR, US05352A1007

Avantor refocuses on biopharma and lab services, shares in S&P 500 health tech cohort spotlight

22.06.2026 - 17:20:36 | ad-hoc-news.de

Avantor is sharpening its biopharma and lab-services profile as a core S&P 500 health technology supplier. The stock sits near the lower end of its 52-week range while peers like Thermo Fisher and Danaher remain key benchmarks for investors.

AVTR, US05352A1007
AVTR, US05352A1007

By Stefan Krueger, Long-Term & Business Model desk. Reviewed prior to publication on 2026-06-22, 17:15.

Avantor (US05352A1007) sits in the S&P 500 health technology cohort as a key supplier to laboratories and biopharma producers worldwide, with its shares trading on the NYSE under the ticker AVTR. On sector level, investors frequently compare the stock with larger peers Thermo Fisher and Danaher when assessing long-term positioning and valuation.

How Avantor earns its money

Avantor generates most of its revenue from consumables, chemicals and single-use products used in biopharmaceutical manufacturing, academic research and industrial laboratories, complemented by services and equipment distribution. The group positions itself as a one-stop platform that combines proprietary brands with third-party products in categories such as high-purity process chemicals, lab reagents, filtration media and chromatography resins.

Biopharma exposure in focus

Biopharma and healthcare customers represent Avantor’s largest end-market, covering biologics, vaccines and advanced therapies production where demand for sterile and single-use products has structurally increased over the past decade. This segment naturally aligns the company with innovation trends in cell and gene therapies, although order patterns can be cyclical when customers digest inventories after strong build-up phases, as sector commentary around suppliers like Thermo Fisher and Danaher has shown in recent years.

Go deeper

Background and price data on Avantor

All current news, historical quotes and regulatory disclosures on Avantor are collected in the dedicated topic section for the AVTR listing.

What the company sells in practice

In practical terms, one representative Avantor product line is its J.T.Baker brand of high-purity laboratory and process chemicals, which includes solvents and reagents used for analytical testing and biopharmaceutical production. These products form part of customers’ everyday workflows and are often purchased on recurring schedules, supporting a structurally consumables-heavy revenue mix.

Where the stock trades today

The Avantor shares (US05352A1007) most recently traded on the NYSE at a single-digit price level in US dollars, with a 52-week range that extends from the upper single digits into the mid-teens according to independent quote services. The exact latest price and market capitalization can be checked in real time on the NYSE or major financial data platforms.

Avantor at a glance

  • Company: Avantor, Inc.
  • ISIN: US05352A1007
  • WKN: (not available)
  • Ticker: AVTR
  • Trading venue: NYSE
  • Price (as of latest available close): single-digit USD level
  • Market cap: multi-billion USD range (as of latest data)
  • Sector / industry: Health technology / life-science tools and services
  • Index membership: S&P 500
  • Next earnings date: not officially scheduled

More on the Avantor shares in social media

This text is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell securities, or any other form of financial service. Investors should conduct their own research and consider multiple information sources.

en | US05352A1007 | AVTR | boerse | 69604204 | bgmi